Actively Recruiting
Inflammatory Mediators of Acute Kidney Injury in Intensive Care
Led by Uppsala University · Updated on 2026-01-12
100
Participants Needed
1
Research Sites
434 weeks
Total Duration
On this page
Sponsors
U
Uppsala University
Lead Sponsor
M
Maastricht University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Acute kidney injury (AKI) affects more than 50% of patients admitted to the intensive care unit. The most common underlying cause is sepsis. Severe AKI in combination with sepsis is associated with high mortality. The mechanisms for sepsis-induced AKI are largely unknown. Our hypothesis is that the inflammatory response to an infection cause collateral damage to host tissue and contributes to the development of AKI. In this study we want to investigate the presence of novel inflammatory mediators in patients with sepsis, patients subjected to major surgery (sterile inflammation) and non-inflamed patients and correlate their levels with the risk for AKI.
CONDITIONS
Official Title
Inflammatory Mediators of Acute Kidney Injury in Intensive Care
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted to the intensive/post operative care unit
- Patients with septic shock
- Patients post major surgery
- Patients after intoxication with a chemical compound
You will not qualify if you...
- Pregnancy
- Breast feeding
- Chronic kidney disease
- Intoxication with nephrotoxic compound
- Lack of informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Akademiska sjukhuset, Centraloperation
Uppsala, Uppsala County, Sweden, 75185
Actively Recruiting
Research Team
S
Sara Bulow, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here